Meta-analysis of the effects of SLCO1B1 gene polymorphisms on the efficacy and safety of rosuvastatin
OBJECTIVE To study the correlation between SLCO1B1(521T＞C and 388A＞G)gene polymorphisms and the efficacy and safety of rosuvastatin.METHODS Retrieved from PubMed,Embase,Cochrane Library,PharmGKB,CNKI database and Wanfang database,the studies about the effects of 521T＞C and 388A＞G gene polymorphisms on the efficacy and safety of rosuvastatin were collected during the inception to Dec.2023.The included data were analyzed by using RevMan 5.3 software.RESULTS A total of 16 studies were included.The results of meta-analysis showed that 521T＞C gene polymorphism was significantly correlated with the efficacy of rosuvastatin.In the dominant gene model,compared with TT genotype,CC+TC genotype significantly improved the efficacy of rosuvastatin in raising high-density lipoprotein cholesterol(HDL-C)[MD=2.38,95%CI(0.61,4.16),P=0.009 0].In the homozygous gene model,compared with TT genotype,CC genotype significantly improved the efficacy of rosuvastatin in reducing total cholesterol[MD=-7.50,95%CI(-13.05,-1.95),P=0.008 0].In heterozygous gene model,compared with TT genotype,TC genotype significantly improved rosuvastatin in reducing low-density lipoprotein cholesterol(LDL-C)[MD=-5.14,95%CI(-9.74,-0.53),P=0.03]and increasing HDL-C[MD=5.67,95%CI(2.61,8.73),P=0.000 3].388A＞G gene polymorphism was also significantly correlated with the efficacy of rosuvastatin.In dominant or homozygous gene models,compared with AA genotype,GG+AG genotype[MD=-6.88,95%CI(-7.46,-6.30),P＜0.000 1]or GG genotype[MD=-9.23,95%CI(-9.41,9.04),P＜0.000 1]significantly improved the efficacy of rosuvastatin in lowering LDL-C.In the heterozygous gene model,compared with AA genotype,AG genotype significantly improved the efficacy of rosuvastatin in lowering LDL-C[MD=-3.00,95%CI(-3.19,-2.82),P＜0.000 1],total cholesterol[MD=-5.80,95%CI(-6.00,-5.59),P＜0.000 1]and triglyceride[MD=-11.79,95%CI(-19.57,-4.02),P=0.003 0].In the recessive gene model,compared with AA+AG genotype,GG genotype significantly improved the therapeutic efficacy of rosuvastatin in reducing LDL-C[MD=-4.31,95%CI(-8.47,-0.14),P=0.040 0]and elevating HDL-C[MD=4.49,95%CI(2.20,6.77),P=0.000 1].Under 4 gene models,there was a significant correlation between 521T＞C gene polymorphism and rosuvastatin-related ADR probability(P＜0.05),but no significant correlation was found in 388A＞G gene polymorphism(P＞0.05).CONCLUSIONS The polymorphism of 521T＞C gene is significantly related to the efficacy and safety of rosuvastatin in lowering lipid,and the C allele may be one of the factors leading to the increase of rosuvastatin in lipid-lowering efficacy and ADR.388A＞G gene polymorphism is significantly associated with the lipid-lowering efficacy of rosuvastatin,but not with its safety.
万方数据
维普
